Real Time Chart
Stock Profile
Stock Fundamentals
Balance sheet

Financials

Splits

Dividends

Income

Cash Flow

Financials as reported

Financials As Reported

accession Number 0001725160-23-000113

accounts Payable Current 12,818,000

accumulated Depreciation Depletion And Amortization Property Plant And Equipment 3,093,000

accumulated Other Comprehensive Income Loss Net Of Tax --556,000

allocated Share Based Compensation Expense 13,733,000

amendment Flag false

assets 489,342,000

assets Current 410,226,000

available For Sale Securities Debt Maturities Single Maturity Date 1970-01-05

cash And Cash Equivalents At Carrying Value 36,280,000

cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents 38,907,000

cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect --6,789,000

cik 1,725,160

city Area Code 212

common Stock Par Or Stated Value Per Share 0.001

common Stock Shares Authorized 250,000,000

common Stock Shares Issued 59,442,342

common Stock Shares Outstanding 59,442,342

comprehensive Income Net Of Tax --62,422,000

current Fiscal Year End Date --12-31

date Filed 2023-05-10

depreciation Depletion And Amortization 360,000

document Fiscal Period Focus Q1

document Fiscal Year Focus 2,023

document Period End Date 2023-03-31

document Transition Report false

document Type 10-Q

earnings Per Share Basic -1.07

earnings Per Share Diluted -1.07

entity Address Address Line 1 1359 Broadway

entity Address City Or Town New York,

entity Address Postal Zip Code 10,018

entity Address State Or Province NY

entity Central Index Key 1,725,160

entity Current Reporting Status Yes

entity Emerging Growth Company false

entity File Number 001-39263

entity Filer Category Large Accelerated Filer

entity Incorporation State Country Code DE

entity Interactive Data Current Yes

entity Name Zentalis Pharmaceuticals, Inc.

entity Registrant Name Zentalis Pharmaceuticals, Inc.

entity Shell Company false

entity Small Business false

entity Tax Identification Number 82-3607803

income Tax Expense Benefit 108,000

irs Number 823,607,803

lessee Operating Lease Liability Payments Due 71,758,000

lessee Operating Lease Liability Payments Due Next Twelve Months 6,486,000

lessee Operating Lease Liability Payments Due Year Four 7,451,000

lessee Operating Lease Liability Payments Due Year Three 7,278,000

lessee Operating Lease Liability Payments Due Year Two 6,799,000

lessee Operating Lease Liability Undiscounted Excess Amount 24,740,000

liabilities 103,677,000

liabilities And Stockholders Equity 489,342,000

liabilities Current 56,358,000

local Phone Number 433-3791

net Cash Provided By Used In Financing Activities 373,000

net Cash Provided By Used In Investing Activities 42,121,000

net Cash Provided By Used In Operating Activities --49,283,000

net Income Loss --63,219,000

operating Expenses 64,953,000

operating Income Loss --64,953,000

operating Lease Liability 47,018,000

operating Lease Liability Current 2,247,000

operating Lease Liability Noncurrent 44,771,000

operating Lease Right Of Use Asset 37,475,000

other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax 797,000

other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent 797,000

other Liabilities Noncurrent 1,792,000

payments To Acquire Available For Sale Securities Debt 63,879,000

payments To Acquire Property Plant And Equipment 0

period End 1,680,220,800,000

period Start 1,672,531,200,000

proceeds From Maturities Prepayments And Calls Of Available For Sale Securities 106,000,000

property Plant And Equipment Gross 9,973,000

property Plant And Equipment Net 6,880,000

report Link https://www.sec.gov/Archives/edgar/data/1725160/000172516023000113/zntl-20230331_htm.xml

research And Development Expense 48,584,000

retained Earnings Accumulated Deficit --659,584,000

share Based Compensation 13,733,000

stockholders Equity 385,487,000

trading Symbol ZNTL

update 1970-01-01

weighted Average Number Of Diluted Shares Outstanding 59,277,000

weighted Average Number Of Shares Outstanding Basic 59,277,000

id REPORTED_FINANCIALS

key ZNTL

subkey 10-Q

date 2023-05-10

updated 2023-05-11
Symbol Info
Symbol Over View
Technical Analysis

ZNTL stock fundamentals - financials as reported

Financials As Reported

accession Number 0001725160-23-000113
accounts Payable Current 12,818,000
accumulated Depreciation Depletion And Amortization Property Plant And Equipment 3,093,000
accumulated Other Comprehensive Income Loss Net Of Tax --556,000
allocated Share Based Compensation Expense 13,733,000
amendment Flag false
assets 489,342,000
assets Current 410,226,000
available For Sale Securities Debt Maturities Single Maturity Date 1970-01-05
cash And Cash Equivalents At Carrying Value 36,280,000
cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents 38,907,000
cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect --6,789,000
cik 1,725,160
city Area Code 212
common Stock Par Or Stated Value Per Share 0.001
common Stock Shares Authorized 250,000,000
common Stock Shares Issued 59,442,342
common Stock Shares Outstanding 59,442,342
comprehensive Income Net Of Tax --62,422,000
current Fiscal Year End Date --12-31
date Filed 2023-05-10
depreciation Depletion And Amortization 360,000
document Fiscal Period Focus Q1
document Fiscal Year Focus 2,023
document Period End Date 2023-03-31
document Transition Report false
document Type 10-Q
earnings Per Share Basic -1.07
earnings Per Share Diluted -1.07
entity Address Address Line 1 1359 Broadway
entity Address City Or Town New York,
entity Address Postal Zip Code 10,018
entity Address State Or Province NY
entity Central Index Key 1,725,160
entity Current Reporting Status Yes
entity Emerging Growth Company false
entity File Number 001-39263
entity Filer Category Large Accelerated Filer
entity Incorporation State Country Code DE
entity Interactive Data Current Yes
entity Name Zentalis Pharmaceuticals, Inc.
entity Registrant Name Zentalis Pharmaceuticals, Inc.
entity Shell Company false
entity Small Business false
entity Tax Identification Number 82-3607803
income Tax Expense Benefit 108,000

irs Number 823,607,803
lessee Operating Lease Liability Payments Due 71,758,000
lessee Operating Lease Liability Payments Due Next Twelve Months 6,486,000
lessee Operating Lease Liability Payments Due Year Four 7,451,000
lessee Operating Lease Liability Payments Due Year Three 7,278,000
lessee Operating Lease Liability Payments Due Year Two 6,799,000
lessee Operating Lease Liability Undiscounted Excess Amount 24,740,000
liabilities 103,677,000
liabilities And Stockholders Equity 489,342,000
liabilities Current 56,358,000
local Phone Number 433-3791
net Cash Provided By Used In Financing Activities 373,000
net Cash Provided By Used In Investing Activities 42,121,000
net Cash Provided By Used In Operating Activities --49,283,000
net Income Loss --63,219,000
operating Expenses 64,953,000
operating Income Loss --64,953,000
operating Lease Liability 47,018,000
operating Lease Liability Current 2,247,000
operating Lease Liability Noncurrent 44,771,000
operating Lease Right Of Use Asset 37,475,000
other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax 797,000
other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent 797,000
other Liabilities Noncurrent 1,792,000
payments To Acquire Available For Sale Securities Debt 63,879,000
payments To Acquire Property Plant And Equipment 0
period End 1,680,220,800,000
period Start 1,672,531,200,000
proceeds From Maturities Prepayments And Calls Of Available For Sale Securities 106,000,000
property Plant And Equipment Gross 9,973,000
property Plant And Equipment Net 6,880,000
report Link https://www.sec.gov/Archives/edgar/data/1725160/000172516023000113/zntl-20230331_htm.xml
research And Development Expense 48,584,000
retained Earnings Accumulated Deficit --659,584,000
share Based Compensation 13,733,000
stockholders Equity 385,487,000
trading Symbol ZNTL
update 1970-01-01
weighted Average Number Of Diluted Shares Outstanding 59,277,000
weighted Average Number Of Shares Outstanding Basic 59,277,000
id REPORTED_FINANCIALS
key ZNTL
subkey 10-Q
date 2023-05-10
updated 2023-05-11